Jan. 14 at 2:44 PM
$MYNZ Mainz Biomed pancreatic update looks like a small PR, but for a microcap it is exactly the kind of step the market reprices once there is public, citable data
What they announced
• At AACR 2026 (April 17 to 22, 2026, San Diego) the company will present verification study results in pancreatic cancer (PDAC)
• Format blood derived mRNA biomarkers plus AI assisted modeling
• Goal differentiate PDAC from benign conditions, including IPMN
• Details are expected in the AACR online proceedings, with a specific date and publication trail
Why PDAC versus benign matters
Many early diagnostics look strong on cancer versus healthy. Real world workflows include look alike benign conditions, where false positives, unnecessary invasive follow ups, and weak adoption show up. Positioning the work around PDAC and benign including IPMN is a clinically relevant framing that investors tend to respect more than a headline metric alone
Prior numbers for context
Discovery step (March 2025)
• Dataset 285 subjects, including 35 pancreatic cancer patients
• Biomarkers plus algorithm reported 95 percent sensitivity and 98 percent specificity
This supports that a signal exists on a non trivial dataset
Feasibility step (October 2025)
• Panels were reduced from 18 licensed biomarkers into more compact sets
• Leading panel reported 100 percent sensitivity and 95 percent specificity in a 30 subject cohort, cancer versus healthy controls
This suggests the team has been working on simplifying the panel while maintaining performance
The AACR verification presentation is the next step, showing performance beyond ideal controls and into a more clinically relevant PDAC and benign setting. The cohort is still small at 30, but an AACR proceedings entry creates a reference point the market can anchor to
Trading mechanics
Microcaps often rerate through a sequence of de risk steps rather than waiting for revenues
• discovery to feasibility to verification on a major public venue to the next study design
Each step tends to broaden the buyer base because the story looks more clinical and less like a lab project. If the proceedings include standard metrics like AUC, error breakdown, cohort composition in benign, and stage details, the market can start pricing pancreatic optionality more seriously
Why Mainz Biomed is not only a pancreatic story. Pancreas is upside optionality, while CRC screening is the core engine with disclosed KPI history and visible timers
CRC stack and disclosed numbers
• ColoAlert is CE IVD, combining FIT hemoglobin with PCR markers including KRAS codon 12 and 13 and BRAF codon 600
• Disclosed performance sets include
ColoFuture EU CRC sensitivity 94 percent, specificity 97 percent, advanced adenoma sensitivity 80 percent, advanced adenoma specificity 95 percent
eAArly DETECT US CRC sensitivity 97 percent, specificity 97 percent, advanced adenoma sensitivity 82 percent, advanced adenoma specificity 97 percent
Pooled n 690 CRC sensitivity 92 percent, specificity 90 percent, advanced adenoma sensitivity 82 percent, advanced adenoma specificity 90 percent
For traders this matters because there is an established scoreboard on the core program, so pancreas can be framed as a bonus upside driver
2026 timers the tape can front run
• Expected year end financial results in March 2026
• eAArly DETECT 2 about 2,000 average risk patients, FIT plus proprietary mRNA biomarkers plus an AI developed algorithm, with disclosed logic around an interim read at about 50 percent and a target completion window in early or first half 2026
• AACR 2026 April 17 to 22, 2026 pancreatic verification results plus proceedings publication
This reads as a scheduled chain of checkpoints rather than an open ended plan
